WallStreetZenWallStreetZen

NASDAQ: MLYS
Mineralys Therapeutics Inc Stock Ownership - Who owns Mineralys Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Mineralys Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
David Malcom RodmanChief Medical Officer2025-04-146,348$1.08
$6.86kBuy
David Malcom RodmanChief Medical Officer2025-04-148,400$14.83
$124.57kSell
David Malcom RodmanChief Medical Officer2025-04-142,966$13.69
$40.61kSell
Adam Scott LevyCFO and Secretary2025-04-1110,757$12.06
$129.69kSell
Jon CongletonChief Executive Officer2025-04-1115,319$12.19
$186.80kSell
David Malcom RodmanChief Medical Officer2025-04-011,606$1.08
$1.73kBuy
David Malcom RodmanChief Medical Officer2025-04-0122,406$16.77
$375.75kSell
David Malcom RodmanChief Medical Officer2025-04-012,791$16.02
$44.72kSell
David Malcom RodmanChief Medical Officer2025-04-0130,574$15.00
$458.55kSell
Ra Capital Management LPDirector2025-03-131,296,296$13.50
$17.50MBuy

1 of 6

MLYS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when MLYS insiders and whales buy or sell their stock.

MLYS Shareholders

What type of owners hold Mineralys Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Samsara Biocapital GP LLC21.57%10,749,832$143.51MInsider
Srinivas Akkaraju21.57%10,749,832$143.51MInsider
Catalys Pacific LLC17.35%8,644,579$115.41MInstitution
Brian Taylor Slingsby17.35%8,644,579$115.41MInsider
Samsara Biocapital LLC10.18%5,074,916$67.75MInstitution
Ra Capital Management LP9.73%4,850,984$64.76MInstitution
Ra Capital Management LP7.49%3,734,458$49.86MInsider
Hbm Healthcare Investments Cayman Ltd6.46%3,218,106$42.96MInsider
Tcg Crossover Management LLC4.96%2,470,265$32.98MInstitution
Blackrock Inc4.29%2,138,522$28.55MInstitution

1 of 3

MLYS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
MLYS54.82%45.18%Net BuyingNet Buying
DNTH51.06%48.94%
LENZ38.92%61.08%Net BuyingNet Buying
AVBP73.06%26.94%Net Buying
NUVB55.45%44.55%Net BuyingNet Buying
View Top Biotech Stocks

Mineralys Therapeutics Stock Ownership FAQ

Who owns Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ: MLYS) is owned by 93.23% institutional shareholders, 76.82% Mineralys Therapeutics insiders, and 0.00% retail investors. Samsara Biocapital GP LLC is the largest individual Mineralys Therapeutics shareholder, owning 10.75M shares representing 21.57% of the company. Samsara Biocapital GP LLC's Mineralys Therapeutics shares are currently valued at $142.33M.

If you're new to stock investing, here's how to buy Mineralys Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.